Results 151 to 160 of about 3,715,425 (177)

Effects of benapryzine, a new antiparkinson drug, on dopamine uptake into corpus striatum

European Journal of Pharmacology, 1974
M G Palfreyman, Michael S G Clark
exaly  

Antiparkinson Drug Use and Adherence in Medicare Part D Beneficiaries With Parkinson’s Disease

Clinical Therapeutics, 2013
Yu-Jung Jenny Wei, Linda Simoni-Wastila, Lisa M Shulman   +2 more
exaly  

Antiparkinson Drug Adherence and Its Association with Health Care Utilization and Economic Outcomes in a Medicare Part D Population

Value in Health, 2014
Yu-Jung Jenny Wei, Linda Simoni-Wastila, Lisa M Shulman   +2 more
exaly  

Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors

Psychopharmacology, 2006
Anne Dekeyne, Millán Mark J, Dekeyne Anne   +2 more
exaly  

Use of antiparkinson medications among elderly Medicare beneficiaries with Parkinson's disease

American Journal of Geriatric Pharmacotherapy, 2010
Yu-Jung Jenny Wei, Bruce Stuart, Ilene H Zuckerman   +2 more
exaly  

Parkinson’s disease, antiparkinson medicines, and driving

Expert Review of Neurotherapeutics, 2016
F Javier Alvarez
exaly  

[Tranquilizing agents: extrapyramidal and antiparkinsonism activities].

La Vie medicale au Canada francais, 1973
J M, Bordeleau, L, Tétreault, R, Elie
openaire   +1 more source

An experimental evaluation of the euphoric properties of antiparkinson drugs on psychotic patients

Acta Psychiatrica Scandinavica, 1986
K G Götestam
exaly  

[Anticholinergic antiparkinson agents].

Soins. Psychiatrie, 1989
openaire   +1 more source

Antiparkinson agent/Quetiapine/Sertraline

Reactions Weekly
openaire   +1 more source